Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Saxenda

- PMLiVE

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Halts three studies because of safety concerns

- PMLiVE

Novo Nordisk awakens its ‘Sleeping Beauty’

Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott

- PMLiVE

New drugs drive Novo Nordisk despite insulin price pressures

Sales growth of new products up in Q4 but trouble forecasted this year

- PMLiVE

Novo Nordisk gets MACE prevention claim for Ozempic in US

Key product for the future growth of Novo's diabetes franchise

- PMLiVE

Keeping up the fight against HIV and using the lessons to tackle other threats

Danny Buckland interviews Gilead’s Mike Elliott

- PMLiVE

Healthanuary?

Whether you are taking part in Dry January, Veganuary, or any other health regime, just keep going!

Page & Page and Partners

- PMLiVE

Lilly extends range of cut-price insulins in the US

Announces discounts in response to increasing pricing criticism

- PMLiVE

Novo bolstered by new diabetes, obesity products

Danish drug-maker has now raised its full-year sales forecast

- PMLiVE

Novo Nordisk taps Noom for digital help with its push into obesity

Could help to strengthen Saxenda franchise in treatment of obesity

- PMLiVE

Novo Nordisk gets FDA okay for new diabetes hope

Potential to combat increasing competition and pricing pressures

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

Novo Nordisk shareholder revolt reaches Europe

Accused of lacking transparency over pricing pressures

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links